523 related articles for article (PubMed ID: 16151585)
21. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
22. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
[TBL] [Abstract][Full Text] [Related]
23. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
24. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia.
Etienne A; Esterni B; Charbonnier A; Mozziconacci MJ; Arnoulet C; Coso D; Puig B; Gastaut JA; Maraninchi D; Vey N
Cancer; 2007 Apr; 109(7):1376-83. PubMed ID: 17326052
[TBL] [Abstract][Full Text] [Related]
25. CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype.
Chang H; Yeung J; Brandwein J; Yi QL
Leuk Res; 2007 Feb; 31(2):157-62. PubMed ID: 16837044
[TBL] [Abstract][Full Text] [Related]
26. [Analysis of prognostic variables in childhood acute myeloid leukemia].
Gu LJ; Tie LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Ye H; Wang YP; Dong L
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):10-3. PubMed ID: 16732931
[TBL] [Abstract][Full Text] [Related]
27. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
28. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
van Rhenen A; Feller N; Kelder A; Westra AH; Rombouts E; Zweegman S; van der Pol MA; Waisfisz Q; Ossenkoppele GJ; Schuurhuis GJ
Clin Cancer Res; 2005 Sep; 11(18):6520-7. PubMed ID: 16166428
[TBL] [Abstract][Full Text] [Related]
29. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
[TBL] [Abstract][Full Text] [Related]
30. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Larson RA
Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
[TBL] [Abstract][Full Text] [Related]
31. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation.
Kim DH; Sohn SK; Kim JG; Lee NY; Sung WJ; Baek JH; Suh JS; Lee KS; Lee KB
Ann Hematol; 2005 Jan; 84(1):25-32. PubMed ID: 15349754
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
[TBL] [Abstract][Full Text] [Related]
33. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome.
Chang H; Brandwein J; Yi QL; Chun K; Patterson B; Brien B
Leuk Res; 2004 Oct; 28(10):1007-11. PubMed ID: 15289011
[TBL] [Abstract][Full Text] [Related]
34. [Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia].
Bao L; Jiang B; Huang XJ; Wang DB; Qiu JY; Lu XJ; Chen H; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):31-4. PubMed ID: 15946506
[TBL] [Abstract][Full Text] [Related]
35. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
Pfirrmann M; Ehninger G; Thiede C; Bornhäuser M; Kramer M; Röllig C; Hasford J; Schaich M;
Lancet Oncol; 2012 Feb; 13(2):207-14. PubMed ID: 22197676
[TBL] [Abstract][Full Text] [Related]
36. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
Malagola M; Damiani D; Martinelli G; Michelutti A; Cesana B; Vivo AD; Piccaluga PP; Ottaviani E; Candoni A; Geromin A; Tiribelli M; Fanin R; Testoni N; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filí C; Baccarani M; Russo D
Br J Haematol; 2007 Jan; 136(1):87-95. PubMed ID: 17222198
[TBL] [Abstract][Full Text] [Related]
37. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome.
Schaich M; Harbich-Brutscher E; Pascheberg U; Mohr B; Soucek S; Ehninger G; Illmer T
Haematologica; 2002 May; 87(5):455-64. PubMed ID: 12010657
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia.
Mollee P; Gupta V; Song K; Reddy V; Califaretti N; Tsang R; Crump M; Keating A
Bone Marrow Transplant; 2004 Jun; 33(12):1201-8. PubMed ID: 15094745
[TBL] [Abstract][Full Text] [Related]
39. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.
Palmieri S; Ferrara F; Leoni F; Ciolli S; Pollio F; D'Amico MR; Celentano M; Viola A; Vicari L; Izzo B; Pane F
Hematol Oncol; 2007 Mar; 25(1):1-5. PubMed ID: 17036374
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
